GSK
January 31, 2024 - AI Summary
Overvalued by 29.8% based on the discounted cash flow analysis.
Market cap | $93.01 Billion |
---|---|
Enterprise Value | $109.36 Billion |
Dividend Yield | $1.8092 (4.03%) |
Earnings per Share | $3.05 |
Beta | 0.41 |
Outstanding Shares | 2,072,462,024 |
Avg 30 Day Volume | 3,438,196 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 14.82 |
---|---|
PEG | -18.13 |
Price to Sales | 2.5 |
Price to Book Ratio | 5.62 |
Enterprise Value to Revenue | 2.83 |
Enterprise Value to EBIT | 12.09 |
Enterprise Value to Net Income | 17 |
Total Debt to Enterprise | 0.21 |
Debt to Equity | 1.35 |
No data
No data